AlphAIalphai — Financial news for AI agents
FinvizDEC 273 min read$ABSI

Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential

Absci Corporation (NASDAQ: ABSI) has garnered a full buy consensus among analysts, with a median price target suggesting a 150.70% upside potential. H.C. Wainwright recently reaffirmed a 'Buy' rating and raised the price target to $8, citing the incorporation of ABS-201, an AI-designed antibody for androgenetic alopecia, into the company's model. Preclinical data indicates ABS-201's strong potential to stimulate hair growth and regenerate stem cells.

Original reporting
Finviz · Rameen Kasana
Published Dec 27, 2025, 6:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Dec 27, 2025, 6:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential — source image
Source · Finviz
Decision brief

The 30-second read

$ABSIBullishHigh
01

Why it matters

The analyst consensus and incorporation of AI-designed therapeutics suggest strong growth prospects, potentially leading to stock appreciation.

02

Market read

The news indicates a positive catalyst for ABSI, with potential ripple effects in biotech investments and related sectors.

03

What to watch

Market volatility, broader biotech sector risks, and competition from other antibody therapies could impact stock performance.

Timing: Immediate to short-term (next 1-3 months)

Background

Absci Corporation is a biotech firm focusing on AI-driven antibody discovery and development.

Company-level read

Ticker impact

$ABSIBullishHigh confidence
Context

High relevance due to recent analyst consensus and potential upside.

Expected impact

Significant upward movement expected if the company meets or exceeds analyst expectations.

Evidence & confidence

The consensus buy rating and substantial upside target, combined with positive preclinical data, support a bullish outlook. However, reliance on preclinical data introduces some uncertainty.

Market effects

Sector

Potential positive impact on biotechnology and life sciences sectors due to innovative antibody development.

Regional

Primarily US-focused, with possible influence on biotech indices.

Global

Moderate; biotech sector's global influence depends on clinical trial outcomes and regulatory approvals.

Counterpoint

What could challenge this read

Potential overestimation of upside if preclinical results do not translate into clinical success or regulatory approval is delayed.

Key entities

  • Company
    Absci Corporation

    Biotech company specializing in AI-driven antibody discovery.

  • Product
    ABS-201

    AI-designed antibody for androgenetic alopecia with promising preclinical data.

  • Financial Institution
    H.C. Wainwright

    Analyst firm reaffirming buy rating and raising price target.

Read at source← All news

Related articles

JUN 26
$ABSIMed

Absci (NASDAQ:ABSI) Shares Gap Up Following Analyst Upgrade

Absci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.

themarketsdaily.com3 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min
AUG 8
$BWAMed

Why Is BorgWarner (BWA) Expanding Its Edge In China And EV Systems?

BorgWarner (NYSE:BWA) said it won new variable cam timing system contracts in Europe and China, including a conquest award, and that the wins expand positions with existing customers and replace a competitor on a China program. It also received awards for high voltage inverters and integrated drive modules for hybrid and EV platforms, which it said add to backlog.

simplywall.st4 min